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Abstract
Background—Apparent treatment resistant hypertension (aTRH) is defined as uncontrolled
hypertension despite the use of ≥3 antihypertensive medication classes or controlled hypertension
while treated with ≥ 4 antihypertensive medication classes. We evaluated the association of aTRH
with incident stroke, coronary heart disease (CHD) and all-cause mortality.
Methods—Participants from the population-based REasons for Geographic And Racial
Differences in Stroke (REGARDS) Study treated for hypertension with aTRH (n=2,043) and
without aTRH (n=12,479) were included. aTRH was further categorized as controlled aTRH (≥ 4
medication classes and controlled hypertension) and uncontrolled aTRH (≥ 3 medication classes
and uncontrolled hypertension).
Results—Over a median of 5.9, 4.4, and 6.0 years of follow-up the multivariable adjusted hazard
ratio for stroke, CHD, and all-cause mortality associated with aTRH versus no aTRH was 1.25
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(0.94 – 1.65), 1.69 (1.27 – 2.24), and 1.29 (1.14 – 1.46), respectively. Compared to controlled
aTRH, uncontrolled aTRH was associated with CHD (HR=2.33; 95% CI 1.21 – 4.48), but not
stroke or mortality. Comparing controlled aTRH to no aTRH, risk of stroke, CHD and all-cause
mortality was not elevated.
Conclusion—aTRH was associated with an increased risk for coronary heart disease and all-
cause mortality.
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Introduction
Treatment resistant hypertension (TRH) is defined as uncontrolled hypertension despite the
use of ≥ 3 antihypertensive medication classes or controlled hypertension while treated with
≥ 4 antihypertensive medication classes 1. Although the definition of TRH is widely
accepted and commonly applied in research, the term apparent TRH (aTRH) has been used
for population-based studies unable to exclude cases of pseudoresistance 2. Using data from
the National Health And Nutrition Examination Survey (NHANES) 2005-2008 Egan and
colleagues estimated 11.8% of hypertensive US adults have aTRH2. aTRH prevalence
estimates >10% among persons with hypertension have been reported in several other
studies 3-5.
Hypertension is a major, modifiable risk factor for stroke, coronary heart disease (CHD) and
all-cause mortality 6-8. Cross-sectional studies have found that, among those with
hypertension, persons with aTRH have an increased burden of cardiovascular disease (CVD)
risk factors and a higher 10-year Framingham coronary heart disease (CHD) risk score 2-4.
However, few data are available from prospective studies on the risk for CVD among people
with aTRH. The goal of the current study was to determine whether aTRH is associated with
an increased risk for CVD. To do so, we evaluated the risk for stroke, CHD and all-cause
mortality among 2,043 REasons for Geographic And Racial Differences in Stroke
(REGARDS) participants with aTRH relative to 12,479 REGARDS participants with
controlled hypertension treated with < 4 antihypertensive medication classes or uncontrolled
hypertension treated with 1 or 2 antihypertensive medication classes. aTRH can be stratified
into two subgroups including those with controlled hypertension on ≥4 antihypertensive
medication classes (controlled aTRH) and uncontrolled hypertension on ≥ 3
antihypertensive medication classes (uncontrolled aTRH) 1. Given the association between
level of blood pressure (BP) while on antihypertensive treatment and CVD, we also
evaluated the risk for stroke, CHD and all-cause mortality among REGARDS participants
with uncontrolled versus controlled aTRH 9,10.
Methods
Study Population
The design of the REGARDS study has been described previously 11. Briefly, adults ≥ 45
years of age from all 48 continental US states and the District of Columbia were included. A
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total of 30,239 individuals were enrolled into the study between January 2003 and October
2007. By design, the study oversampled blacks and residents of the “stroke belt” and “stroke
buckle” regions of the US. The “stroke buckle” was defined as coastal North Carolina,
South Carolina, and Georgia and the “stroke belt” as the remainder of North Carolina, South
Carolina, and Georgia as well as Alabama, Mississippi, Tennessee, Arkansas and Louisiana.
We restricted the current analysis to REGARDS participants who were treated for
hypertension as determined by both pill bottle review and self-reported use of
antihypertensive medication (n=14,811). We excluded participants without valid BP
measurements at baseline (n=45) or missing follow up data (n=244). After these exclusions,
14,522 REGARDS participants who were treated for hypertension were included in the
analysis of all-cause mortality (Supplemental Figure 1). Of this group 1,342 participants
reported a history of stroke and were excluded from the analysis of incident stroke and 3,347
participants had a history of CHD and were excluded from the analysis of incident CHD.
The REGARDS study protocol was approved by the Institutional Review Boards governing
research in human subjects at the participating centers and all participants provided
informed consent.
Data Collected at Baseline
Computer-assisted telephone interviews administered by trained staff were used to collect
information on participants’ age, race, sex, smoking status, education, physical activity,
alcohol consumption, prior physician diagnosed co-morbid conditions (e.g., stroke and
myocardial infarction), medication adherence, and age when first diagnosed with
hypertension 12. Medication adherence was assessed by the 4-item Morisky Medication
Adherence Scale (MMAS). MMAS scores have a range from 0 to 4 with higher scores
indicating worse adherence 12. Duration of hypertension was calculated as the age at
diagnosis subtracted from age at the baseline examination. Subsequent to the interview,
trained health professionals conducted in-home examinations that included weight, height,
BP measurements, an electrocardiogram (ECG), the collection of blood and a spot urine
sample, plus a review of prescription and over the counter medications used over the prior 2
week period. C-reactive protein (hsCRP) was determined by particle enhanced
immunonephelometry using the BNII nephelometer (N High Sensitivity CRP; Dade
Behring, Deerfield, IL). Total and high-density lipoprotein (HDL) cholesterol and glucose
were measured by colorimetric reflectance spectrophotometry using the Ortho Vitros
Clinical Chemistry System 950IRC instrument (Johnson & Johnson Clinical Diagnostics,
New Brunswick, NJ). Medication names were recorded and subsequently coded into drug
classes. Information on medication dose was not recorded. History of CHD at baseline was
defined by a self-reported history or ECG evidence of myocardial infarction (MI) or a self-
reported history of a revascularization procedure. History of stroke was defined on the basis
of self-report. Diabetes was defined as a serum glucose ≥126 mg/dL for participants who
had fasted prior to their blood draw, serum glucose ≥200 mg/dL for those who had not
fasted, self-report of a prior diagnosis of diabetes while not pregnant, or current use of
insulin or oral hypoglycemic medications. Using isotope-dilution mass spectrometry
(IDMS)–traceable serum creatinine, estimated glomerular filtration rate (eGFR) was
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation 13. Low eGFR was defined as levels < 60 ml/min/1.73 m2. Albuminuria was
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defined as being present for individuals with a urinary albumin to urinary creatinine ratio ≥
30 mg/g.
Blood Pressure measurement and definition of aTRH—During the in-home
examination, BP was measured two times using aneroid sphygmomanometers following a
standardized protocol by trained examiners. Participants were asked to sit for five minutes
with both feet on the floor prior to the first BP measurement and there was a 30 second rest
between measurements. Based on the average of the two measurements, uncontrolled
hypertension was defined as systolic blood pressure (SBP) ≥ 140 mm Hg or diastolic blood
pressure (DBP) ≥ 90 mm Hg. Controlled hypertension was defined as SBP < 140 mm Hg
and DBP < 90 mm Hg. Antihypertensive medication classes were defined as those listed in
the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure (JNC 7) 14. Single-pill combinations were classified
into individual medication classes. aTRH was defined as uncontrolled hypertension on ≥ 3
antihypertensive medication classes (uncontrolled aTRH) or controlled hypertension on ≥ 4
antihypertensive medication classes (controlled aTRH) 1. No aTRH was defined as
controlled hypertension on < 4 classes of antihypertensive medication or uncontrolled
hypertension on 1 or 2 classes of antihypertensive medication.
Data collected during follow-up
Living participants or their proxies were contacted every 6 months via telephone to assess
new-onset stroke, CHD events and all-cause mortality. Medical records were retrieved for
stroke and CHD-related hospitalizations and deaths. We studied the following outcomes in
the current analyses.
Stroke—Stroke was assessed via self-report of a possible stroke/transient ischemic attack, a
positive response to the stroke symptoms on the Questionnaire for Verifying Stroke-Free
Status resulting in hospitalization during follow-up, or death related to stroke 15. When
potential events were reported, hospital charts were retrieved for adjudication. Stroke was
confirmed by a panel of neurologists according to the World Health Organization (WHO)
definition 16. Events not meeting the WHO definition but characterized by symptoms lasting
<24 hours with neuroimaging consistent with acute infarct or hemorrhage were classified as
clinical strokes. Additionally, medical records in the last year of life, death certificates and
autopsy reports were collected and reviewed to determine if the death was stroke related
following guidelines described. This analysis included WHO–defined as well as clinical
stroke cases 17. Data on incident stroke was available through September 30, 2011.
Coronary Heart Disease—The occurrence of CHD events, defined as nonfatal MI or
CHD death, were also assessed during the follow-up telephone interviews. After report of a
hospitalization or death that potentially could be related to CHD, medical records were
retrieved and the event was adjudicated by trained clinicians following published
guidelines 18,19. Specifically, medical records were examined for the presence of signs or
symptoms suggestive of ischemia; a rising and/or falling pattern in cardiac troponin or
creatine phosphokinase-MB over 6 or more hours with a peak value greater than or equal to
twice the upper limit of normal (diagnostic cardiac enzymes); and ECG changes consistent
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with ischemia or MI, guided by the Minnesota code and classified as evolving diagnostic,
positive, nonspecific or not consistent with ischemia 20,21. Additionally, medical records in
the last year of life, death certificates and autopsy reports were collected and reviewed to
determine if the death was a CHD death following published guidelines described 18,19.
Incident CHD events through December 31, 2009 were available for the current analyses.
All-Cause Mortality—Participant deaths were detected by report of next-of-kin, online
sources (e.g., the Social Security Death Index), and the National Death Index. To obtain
information surrounding the circumstances of participant death, proxies or next-of-kin were
interviewed. Additionally, death certificates and autopsy reports were collected. Deaths
occurring through March 31, 2012 were included in the current analysis.
Statistical Analysis
Participant characteristics were calculated for those with aTRH and those without aTRH,
overall, and for those with uncontrolled and controlled aTRH, separately. Incidence rates for
stroke, CHD, and all-cause mortality were calculated by aTRH status and for participants
with uncontrolled and controlled aTRH, separately. Cox proportional hazards regression
models were used to calculate the hazard ratio (HR) for stroke, CHD and all-cause mortality
associated with aTRH in comparison to no aTRH. HRs were initially adjusted for age, race,
sex, and geographic region of residence (model 1) and further adjusted for waist
circumference, smoking, physical activity, alcohol consumption, statin use, MMAS score,
total cholesterol, HDL-cholesterol, hsCRP and duration of hypertension (model 2). Full
covariate adjustment (model 3) included variables in models 1 and 2 plus low eGFR,
albuminuria, and diabetes. In model 3, the HR for stroke was also adjusted for history of
CHD, the HR for CHD was also adjusted for history of stroke and the HR for all-cause
mortality was adjusted for history of CHD and history of stroke. Also, HRs for stroke, CHD
and all-cause mortality were calculated comparing controlled aTRH to no aTRH,
uncontrolled aTRH to no aTRH, and uncontrolled aTRH to controlled aTRH. The American
Heart Association (AHA) definition states that persons with aTRH should ideally be treated
with a diuretic1. Therefore, we conducted a sensitivity analysis requiring participants to be
taking a diuretic in order to meet the definition of aTRH. For this analysis, we excluded 272
participants who met the definition of aTRH outlined above but who were not taking a
diuretic. We were unable to determine if participants taking 1 or 2 antihypertensive
medication classes with uncontrolled hypertension would have aTRH if they were more
aggressively treated. Therefore, a second sensitivity analysis excluded 2,960 participants in
the no aTRH group who were taking 1 or 2 antihypertensive medication classes with




REGARDS participants with aTRH were older than their counterparts without aTRH, more
commonly black and male and more likely to have a larger waist circumference, low eGFR,
albuminuria, diabetes, and a history of CHD or stroke (Table 1). Persons with aTRH had
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lower total and HDL-cholesterol and were more likely to be taking statins than persons
without aTRH. Duration of hypertension was longer among persons with aTRH, but was not
different among subgroups within aTRH. Black race and albuminuria were more common
among those with uncontrolled versus controlled aTRH. Diabetes, low eGFR and statin use
were more common among those with controlled versus uncontrolled aTRH. The average
number of antihypertensive medication classes was higher among those with controlled
aTRH versus those with uncontrolled aTRH (4.2 ± 0.4 and 3.4 ± 0.6, respectively). More
detailed information about medication classes being taken among those with and without
aTRH is provided in Supplemental Table 1.
aTRH and stroke, CHD and all-cause mortality
The median follow-up was 5.9, 4.4, and 6.0 years for the analysis of stroke, CHD, and all-
cause mortality, respectively. During follow-up there were 83 strokes, 84 CHD events and
452 deaths among those with aTRH; and 348 strokes, 287 CHD events and 1,616 deaths
among those without aTRH (Supplemental Table 2). Overall, 27.0% of deaths were due to
cardiovascular causes. The incidence rates for all three outcomes were higher for those with
versus without aTRH (Figure 1). Also, the incidence rate for each outcome was higher for
participants with uncontrolled versus controlled aTRH in addition to controlled aTRH versus
no aTRH.
After adjustment for age, race, gender, and geographic region of residence (model 1) and
further adjustment in model 2, aTRH was associated with increased HRs for stroke, CHD
and all-cause mortality (Table 2). In the full multivariable adjusted model (model 3) aTRH
in comparison to no aTRH was associated with CHD and all-cause mortality with HRs of
1.69 (1.27 – 2.24) and 1.29 (1.14 – 1.46), respectively. After full multivariable adjustment,
the association of aTRH with stroke was not statistically significant (HR =1.25; 95% CI
0.94-1.65).
When compared to participants with no aTRH, controlled aTRH was associated with an
increased risk for all-cause mortality after initial adjustment (Table 3, panel A). This
association was attenuated after further multivariable adjustment (model 3 HR=1.14; 95%
CI 0.93 – 1.40). The HRs for stroke and CHD were not increased among those with
controlled aTRH in comparison to those without aTRH. Compared to participants without
aTRH, uncontrolled aTRH was associated with an increased risk for CHD and all-cause
mortality; the risk for stroke was increased after initial adjustment, but the HR was
attenuated after full multivariable adjustment in model 3 (Table 3, Panel B). Finally,
uncontrolled aTRH was associated with a statistically significant increased risk for CHD in
comparison to controlled aTRH (Table 4). The HR for stroke and all-cause mortality were
not increased for uncontrolled versus controlled aTRH after adjustment for age, race,
gender, and geographic region of residence or further multivariable adjustment. Results were
markedly similar in sensitivity analyses requiring the use of a diuretic to meet the definition
of aTRH (see Supplemental Tables 3-5). Finally, results were also similar after excluding
participants with uncontrolled hypertension taking 1 or 2 antihypertensive medication
classes from the group without aTRH (see Supplemental Tables 6-7).
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A 2008 scientific statement from the American Heart Association reported on the diagnosis,
evaluation and treatment of TRH 1. The authors noted the prognosis for people with TRH
was unknown. Since that report, several cross-sectional studies have been published
showing aTRH to be associated with an increased prevalence of CVD and CVD risk
factors 2-4,22,23. However, there have been few estimates of CVD risk associated with aTRH
from prospective cohort studies and no studies have compared CVD risk associated with
blood pressure control among people with aTRH 22. The current study, set within a
population-based observational cohort, found aTRH to be associated with an increased risk
for CHD and all-cause mortality. Additionally, among people with aTRH, having
uncontrolled versus controlled hypertension was associated with increased risk for CHD.
Finally, participants with aTRH and controlled blood pressure did not have elevated CVD
risk in comparison to others without aTRH.
Utilizing Kaiser Permanente healthcare systems data the Cardiovascular Disease Research
Network (CVRN) reported the multivariable adjusted HR for the composite outcome of
death, stroke, MI, chronic kidney disease (CKD) or heart failure comparing individuals with
aTRH versus those without aTRH was 1.47 (95% CI 1.33 – 1.62) 23. aTRH was not
associated with risk for any outcome individually, however, few events occurred among the
aTRH group (e.g., 54 deaths, 15 strokes and 9 MIs). The association between aTRH and
outcomes was also investigated in the Reduction of Atherothrombosis for Continued Health
(REACH) registry enriched for patients with atherothrombotic risk factors 24. When
defining aTRH as uncontrolled hypertension on ≥3 antihypertensive medication classes
(similarly to our definition of uncontrolled aTRH), the HR for the composite endpoint of
CVD mortality, MI, or stroke over 4 years of follow-up was 1.11 (95% CI 1.02–1.20).
Additionally, aTRH was associated with stroke, but not CVD mortality or all-cause
mortality. Redefining aTRH as uncontrolled hypertension on 3 antihypertensive medication
classes or ≥4 antihypertensive medication classes regardless of blood pressure control found
no association with stroke but increased risk for all-cause mortality, CVD mortality, non-
fatal MI and heart failure hospitalizations. Although these results cannot be directly
compared to data from the current study, they draw consistent conclusions that persons with
aTRH are at higher risk for CVD outcomes.
It has been hypothesized elevated CVD outcome risk among persons with aTRH versus
others with less severe hypertension is due to increased accumulated blood pressure burden
resulting from more severe hypertension over a longer duration 22. Even after accounting for
duration of hypertension, the association of aTRH with CHD and all-cause mortality
persisted in the current analyses. However, we cannot rule out that blood pressure
differences between the aTRH and no aTRH groups may explain the increased CHD risk
associated with aTRH in our study 25. In fact, baseline blood pressure was similar in those
with controlled aTRH and no aTRH and our results demonstrate no difference in CVD risk
between those two groups.
Other aspects of results presented herein are worthy of comment. Specifically, previous
research demonstrates hypertension is the most powerful risk factor for stroke and that
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hypertension control imparts substantial risk reduction for this outcome 7,26,27. In the current
study, aTRH was associated with increased risk for CHD but not stroke after full
multivariable adjustment. Additionally, hypertension control in aTRH was protective against
CHD but not stroke. Therefore, this pattern of risk is distinct within hypertension and could
be related to the increased prevalence of primary aldosteronism, sleep apnea, arterial
stiffness, and heightened sympathetic tone in aTRH 1. These conditions are each
independently linked to cardiovascular outcomes in the general population 28-33.
Several comorbidities (e.g., diabetes, CKD, history of stroke and history of CHD) may be on
the pathway between aTRH and stroke, CHD or all-cause mortality. If so, adjusting for these
factors could obscure a true effect between aTRH and outcomes 34,35. Therefore, we
considered models with and without adjustment for diabetes, CKD, history of stroke and
history of CHD. Overall, adjustment for these comorbidities attenuated the observed
associations, but did not remove them. Assessing whether comorbidities considered in the
current study are intermediates between aTRH and outcomes or confounders was beyond the
scope of the current study. Continued prospective studies with repeated assessments of these
factors and aTRH are necessary to determine the etiology of outcomes for people with TRH.
This analysis has several strengths and limitations. A relatively small number of CHD and
stroke events were observed among those with aTRH, especially when stratifying by blood
pressure control, resulting in wide confidence intervals for some comparisons. We relied on
self-report for several covariates. We were unable to confirm optimal dosing of
antihypertensive medications as a criterion to define aTRH since dose was not recorded as
part of the pill bottle review in REGARDS. Finally, only two blood pressure measurements
were available from a single study visit. The association between aTRH and outcomes using
blood pressure from more than one visit should be investigated in future studies. Despite
these limitations, several strengths are maintained, including the large national population-
based sample in the REGARDS study, the use of standardized protocols with stringent
quality control procedures for the measurement of BP, and the identification and
adjudication of multiple outcomes, including stroke, CHD and all-cause mortality among
persons with an extreme form of hypertension.
In this large, population-based sample of persons treated for hypertension, having aTRH was
associated with an increased risk for CHD and all-cause mortality but not stroke.
Additionally, among people with aTRH, uncontrolled versus controlled hypertension was
associated with more than a two-fold higher risk of CHD events. Individuals with aTRH and
controlled hypertension did not have elevated CVD risk compared to their counterparts
without aTRH. These observations bolster support for continued research to identify unique
aspects of pathophysiology related to TRH and strive for continued improvements in
treatment paradigms to achieve hypertension control within this patient group.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Incidence rates of stroke, coronary heart disease, and all-cause mortality among REGARDS
participants with and without apparent treatment resistant hypertension.
aTRH = apparent treatment resistant hypertension; systolic blood pressure ≥ 140 mm Hg or
diastolic blood pressure ≥ 90 mm Hg with ≥ 3 antihypertensive medication classes
(uncontrolled aTRH) or systolic blood pressure < 140 mmHg and diastolic blood pressure<
90 mm Hg and treatment with ≥ 4 antihypertensive medication classes (controlled aTRH).
No aTRH = no apparent treatment resistant hypertension; systolic blood pressure < 140
mmHg and diastolic blood pressure< 90 mm Hg while treated with < 4 antihypertensive
medication classes or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90
mm Hg while treated with 1 or 2 antihypertensive medication classes.
Bar represents incidence rate, line represents 95% confidence interval.
See Supplemental Table 2 for the incidence rates and 95% confidence intervals.
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Table 1
Baseline characteristics of Reasons for Geographic and Racial Differences in Stroke (REGARDS) study
participants with and without apparent treatment resistant hypertension.
No aTRH aTRH
Characteristic Overall Overall Controlled Uncontrolled
n = 12,479 n = 2,043 n = 723 n = 1,320
Age, years 66.1 ± 9.0 67.6± 8.6 67.2 ± 8.5 67.8 ± 8.7
Black, % 48.6 60.5 55.3 63.3
Male, % 41.9 49.2 51.9 47.8
Geographic Region of Residence, %
 Belt 35.3 34.8 33.9 35.3
 Buckle 21.5 20.7 23.4 19.2
 Other 43.3 44.5 42.7 45.5
Smoking status, %
 Never 44.4 43.8 42.5 44.4
 Past 41.8 44.2 44.7 43.9
 Current 13.8 12.1 12.7 11.7
Physical Activity, %
 None 38.0 44.2 46.2 43.1
 1 – 3 times per week 35.0 33.3 32.2 33.9
 ≥4 times per week 27.0 22.5 21.6 23.0
Alcohol consumption, %
 None 66.6 70.1 69.2 70.5
 Moderate 29.6 27.0 27.5 26.6
 Heavy 3.8 3.0 3.3 2.9
MMAS score, %
 0 69.6 67.1 69.1 66.1
 1 23.1 24.6 24.6 24.6
 ≥ 2 7.4 8.3 6.4 9.4
Waist circumference, cm
 Men 102.3 ± 13.4 107.2 ± 15.2 107.9± 14.1 106.8± 15.8
 Women 96.1 ± 16.1 101.7 ± 17.3 101.5 ± 17.5 101.8± 17.3
HDL-cholesterol, mg/dL 50.9± 15.9 48.2 ± 14.9 46.3 ± 15.1 49.3 ± 14.8
Total cholesterol, mg/dL 188.1 ± 39.9 180.1 ± 40.0 172.8± 38.5 184.1 ± 40.2
hsCRP, mg/dL 2.67 (1.14 – 6.04) 2.86 (1.28 – 6.37) 2.82 (1.26 – 6.29) 2.88 (1.28 – 6.46)
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No aTRH aTRH
Characteristic Overall Overall Controlled Uncontrolled
n = 12,479 n = 2,043 n = 723 n = 1,320
eGFR< 60 ml/min/1.73m2, % 15.3 28.0 31.0 26.4
ACR ≥ 30 mg/g, % 18.0 33.6 27.0 37.1
Statin use, % 40.2 52.1 57.0 49.4
Diabetes, % 28.6 46.2 49.5 44.4
History of coronary heart disease, % 21.0 35.5 40.0 33.1
History of stroke, % 8.5 13.6 13.8 13.4
Systolic blood pressure (mm Hg) 129.6 ± 15.7 142.0 ± 18.3 123.9 ± 10.4 151.8 ± 13.4
Diastolic blood pressure (mm Hg) 77.2 ± 9.5 79.7 ± 11.7 72.7 ± 8.8 83.5 ± 11.2
Hypertension duration (years) 14.2 ± 12.2 20.7 ± 12.9 20.6 ± 12.9 20.7 ± 12.8
Number of antihypertensive medications 1.8 ± 0.7 3.6 ± 0.7 4.2 ± 0.4 3.4 ± 0.6
aTRH = apparent treatment resistant hypertension; systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg with ≥ 3
antihypertensive medication classes (uncontrolled aTRH) or systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mm Hg and
treatment with ≥ 4 antihypertensive medication classes (controlled aTRH).
No aTRH = no apparent treatment resistant hypertension; systolic blood pressure < 140 mmHg and diastolic blood pressure <90 mm Hg while
treated with < 4 antihypertensive medication classes or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mm Hg while treated
with 1 or 2 antihypertensive medication classes.
eGFR = estimated glomerular filtration rate, ACR = albumin-to-creatinine ratio, hsCRP= high sensitivity creactive protein
Table numbers are % or mean ± standard deviation except hsCRP which is median (25th-75th percentiles).
MMAS=Morisky Medication Adherence Scale
Moderate alcohol consumption defined as between 1 and 7 drinks for women and between 1 and 14 drinks for men.
Heavy alcohol consumption defined as >7 drinks for women and >14 drinks for men.
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